{"id":7499,"date":"2026-07-14T10:48:00","date_gmt":"2026-07-14T16:48:00","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=7499"},"modified":"2026-08-15T00:46:19","modified_gmt":"2026-08-15T06:46:19","slug":"avacopan-advocate-study-design","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2026\/07\/14\/7499\/avacopan-advocate-study-design\/","title":{"rendered":"Avacopan ADVOCATE Study Design"},"content":{"rendered":"
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

Much has already been written in recent months about avacopan \/ TAVNEOS, the oral complement C5a receptor antagonist.  It is in the news because of the way the parent company, Chemocentryx, its Adjudication Board and the CRO handled the unblinded data and \u2018re-adjudicated\u2019 the results to achieve the desired outcome, an all-important significant P-value for FDA approval.[1]<\/a>,[2]<\/a>,[3]<\/a><\/p>\n\n\n\n

This drug was developed in ANCA vasculitis for a reason. The market for C5 inhibitors is getting crowded; Alexion has dominated the field with eculizumab and ravulizumab for a long time. Both drugs are biologicals and injectables, of proven benefit in PNH and a few other rare diseases like aHUS.  An oral drug like avacopan would be great to have in these indications, however, Chemocentryx decided to pursue a niche indication, ANCA vasculitis, an area of unmet medical need which held promise for blockbuster potential.<\/p>\n\n\n\n

FDA participated in the design of the single pivotal Phase 3 ANCA vasculitis trial which the Chemocentryx team started in 2017.  The design was complicated; below the FDA slide showing its overall outline.<\/p>\n\n\n\n

The schematic points out an obvious imbalance between treatment arms. Even so it is not immediately obvious how flawed the trial design actually is.  Let us analyze its key features:<\/p>\n\n\n\n

\n

The largest group (approx. 2\/3 of patients) were those started on rituximab \/ RTX.  They received the following treatment regimens:<\/p>\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

Comparator Group A (\u201cprednisone group\u201d)  N=107
ie, tapered prednisone (over 20-wks) then no Rx for the remaining 32 wks<\/strong>
plus a single dose of RTX<\/em><\/p>\n\n\n\n

Active Group B (\u201cavacopan group\u201d)   N=107
ie, avacopan (52-wks) for the entire year<\/strong>
plus a single dose of RTX<\/em><\/p>\n\n\n\n

Everything else being equal, this means that the actual comparison was between a 20-wk prednisone taper and a 52-wk avacopan arm.  In our view, this is a lopsided comparison, with the odds favoring avacopan. <\/p>\n\n\n\n

There was another smaller cohort of patients (approx. 1\/3 of patients) that were started on  CYC –> AZA and received either of the following regimens:<\/p>\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

Comparator group C (\u201cprednisone group\u201d)   N=57
ie, tapered  prednisone (over 20 wks)<\/strong>
plus CYC –> AZA (52-wks)<\/em><\/p>\n\n\n\n

Active Group D (\u201cavacopan group\u201d)    N=59<\/strong>
ie, avacopan (52-wks)<\/strong>
plus CYC –> AZA (52-wks)<\/em><\/p>\n\n\n\n

Here we are dealing with background therapies lasting a full 52-wk BUT if we subtract the contribution of CYC –> AZA (as it is part of both arms) the comparison becomes one of tapered prednisone 20-wks vs 52-wks of avacopan. Therefore, anyway you look at it, this is also a lopsided comparison comparing short-term tapered prednisone (20-wks) with long-term avacopan (52-wks).[4]<\/a><\/p>\n\n\n\n

It sure looks like the design of this Phase 3 trial called ADVOCATE was meant to make avacopan look good.<\/p>\n\n\n\n

NOTE ADDED IN PROOF: This should make it clear why demonstrating superiority was critically important and demanded by FDA. Given this study design, showing a positive trend, non-inferiority, or steroid-sparing alone would not suffice for approval.<\/p>\n\n\n

\n
\"\"<\/a>
ADVOCATE study design. FDA Arthritis Advisory Committee [5]<\/a><\/figcaption><\/figure>\n<\/div>\n\n\n

Well, despite its uneven design, a statistically superior treatment benefit was only seen in the (predominant) subgroup of patients that had no maintenance therapy at all.  In the FDA’s own assessment, there was a “lack of robustness of the superiority assessment”. We wholeheartedly agree. <\/p>\n\n\n\n

With such a slim margin of superiority, lack of confirmation in the ADVOCATE investigator analysis, and lack of a confirmatory 2nd<\/sup> trial, it is not surprising that FDA reviewers in-house were highly critical of the submission.[6]<\/a> When discussed with outside experts at the now defunct FDA Arthritis Advisory Committee, the vote on efficacy was split 9:9. <\/p>\n\n\n\n

So far, we have not even talked about DILI and VBDS yet, toxicities that became even more transparent since the drug was approved.<\/p>\n\n\n\n

There are dark clouds collecting over avacopan.[9]<\/a> There will be more news to share next month after the planned FDA Hearing with Amgen. <\/p>\n\n\n

\n
\"\"<\/a>
Complement Inhibitors and Targets. From Ref. [8]<\/a> (modified)<\/figcaption><\/figure>\n<\/div>\n\n\n

Let us conclude this blog on a positive note.<\/p>\n\n\n\n

Avacopan may not be the best complement C5aR inhibitor for AAV but there is nothing wrong with its underlying rationale.  Inhibition of C5aR1 is a logical next step for a new generation of C5a inhibitors.[7]<\/a>,[8]<\/a> Existing C5 inhibitors are less specific and interfere with the membrane-attack complex (MAC) which can result in  overwhelming meningococcal sepsis. The new classes of C5a and C5aR1 inhibitors are designed to leave the MAC intact.  And that is a good thing.  A more specific C5a agent, even if SC, would be welcome.  An oral drug could be a game-changer. <\/p>\n\n\n\n

ABBREVIATIONS<\/strong>
AAV          ANCA-associated vasculitis
aHUS      acquired hemorrhagic uremic syndrome
ANCA     anti-neutrophil cytoplasmic antibody
AZA          azathioprine
C5, C5a complement factors C5, C5a
C5aR, C5aR1 complement C5a \/ C5a1 receptor
CI confidence interval
CYC         cyclophosphamide
DILI           drug-induced liver injury
MAC        membrane-attack complex (C5-C9)
PNH         paroxysmal nocturnal hemoglobinuria
SC            subcutaneous
VBDS      vanishing bile duct syndrome<\/p>\n\n\n\n

REFERENCES<\/strong>
[1]<\/a> https:\/\/www.healio.com\/news\/rheumatology\/20260515\/fda-seeks-to-withdraw-avacopan-approval-over-alleged-data-manipulation-false-statements<\/a>
[2]<\/a> Jayne D.  Avacopan for the Treatment of ANCA-Associated Vasculitis.  NEJM 2021;384:599
[3]<\/a> Rubin E.  Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis.  NEJM 2026. DOI: 10.1056\/NEJMe2608684
[4]<\/a> CI ranges from FDA review of the Avacopan NDA, based on \u2018re-adjudicated\u2019 data set
[5]<\/a> FDA Arthritis Advisory Committee Meeting, May 6, 2021
[6]<\/a> FDA CDER Multidisciplinary Review & Evaluation, Avacopan NDA 214487. 2021
[7]<\/a> Horiuchi T.  Complement-targeted therapy: development of C5- and C5a-targeted inhibition. Inflamm Regen 36:11, 2016
[8]<\/a> Tesar V.  Complement Inhibition in ANCA-Associated Vasculitis. Front. Immunol. 13:888816, 2022
[9]<\/a> Editorial. The end for avacopan. Lancet Rheumatology Published online July 10, 2026 https:\/\/doi.org\/10.1016\/S2665-9913(26)00225-0<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"

Lopsided Avacopan ADVOCATE Study Design Continue reading Avacopan ADVOCATE Study Design<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":7498,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[227,3,18],"tags":[2724,238,1271,2727,2715,2723,2720,2721,2729,2728,2719,2717,2725,1583,2726,1865,2722,2718,2207,2206,2716],"class_list":["post-7499","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-advocate-study-design","tag-alexion","tag-allphase-pharma-consulting","tag-amgen","tag-avacopan","tag-avacopan-phase-3-study-design","tag-c5a-inhibitor","tag-c5ar-inhibitor","tag-ccx168","tag-chemocentryx","tag-complement-c5-inhibitor","tag-eculizumab","tag-fda-advisory-board","tag-harald-reinhart","tag-imbalance-in-study-design","tag-mac","tag-membrane-attack-complex","tag-ravulizumab","tag-rituxan","tag-rituximab","tag-tavneos"],"jetpack_publicize_connections":[],"jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-1WX","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":7655,"url":"https:\/\/allphasepharma.com\/dir\/2026\/08\/27\/7655\/avacopan-tavneos-follow-up\/","url_meta":{"origin":7499,"position":0},"title":"Avacopan \/ TAVNEOS Follow-Up","author":"Harald","date":"August 27, 2026","format":false,"excerpt":"There was not much for us to report on this summer that would interest our readership... Let\u2019s skip the Fauci \/ Paul senate drama regarding the origins of Covid, with senator Paul taking the role of the Grand Inquisitor and Dr. Fauci the Fifth. The latest act in this screen\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/08\/Avacopan-SLIDER-II-1024x288.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/08\/Avacopan-SLIDER-II-1024x288.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/08\/Avacopan-SLIDER-II-1024x288.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/08\/Avacopan-SLIDER-II-1024x288.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":8049,"url":"https:\/\/allphasepharma.com\/dir\/2026\/10\/25\/8049\/the-never-ending-tavneos-story\/","url_meta":{"origin":7499,"position":1},"title":"The Never-Ending TAVNEOS Story","author":"Harald","date":"October 25, 2026","format":false,"excerpt":"The Tavneos story is getting more bizarre by the day:\u00a0 since January 2026 FDA is haggling with Amgen about a withdrawal.\u00a0 The Agency\u2019s reasoning is described in detail in their April 26 statement and mentioned in numerous Pharma newsletters.\u00a0 The key issue is and was the unblinded re-adjudication of the\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/HR2_Dali-Surreal-Drug-Study-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/HR2_Dali-Surreal-Drug-Study-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/HR2_Dali-Surreal-Drug-Study-1.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":8073,"url":"https:\/\/allphasepharma.com\/dir\/2026\/10\/27\/8073\/igan-therapy-its-getting-crowded-out-there\/","url_meta":{"origin":7499,"position":2},"title":"IgAN Therapy \u2013 It\u2019s Getting Crowded Out There","author":"Harald","date":"October 27, 2026","format":false,"excerpt":"Earlier this year, the NEJM published interim data on atacicept and sibeprenlimab in IgAN, both well-designed Phase 3 pivotal registration trials of promising drugs [1],[2]. Sponsors were clearly anxious to show the world how well their drug is working, but why publish interim results?\u00a0 After all, IA data are usually\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":975,"url":"https:\/\/allphasepharma.com\/dir\/2014\/10\/01\/975\/whats-in-a-name-would-carbavance-still-smell-as-sweet\/","url_meta":{"origin":7499,"position":3},"title":"What\u2019s in a Name?\u00a0 Would \u2018Carbavance\u2019 Still Smell as Sweet?","author":"Harald","date":"October 1, 2014","format":false,"excerpt":"Since the publication of a series of posters at ICAAC 2014, we finally know what\u2019s hidden behind the \u2018Carbavance\u2019 name.\u00a0 \u2018Carbavance\u2019 stands for the combination of meropenem with the B-lactamase inhibitor RPX7009 which The Medicines Company (TMC) inlicensed from Rempex Pharmaceuticals a few years ago.\u00a0 This is the \u2018Carbavance\u2019 which\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/3Roses-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/3Roses-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/3Roses-slider.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":6362,"url":"https:\/\/allphasepharma.com\/dir\/2026\/03\/31\/6362\/igan-therapeutics-the-race-is-on\/","url_meta":{"origin":7499,"position":4},"title":"IgAN Therapeutics – The Race is On","author":"Harald","date":"March 31, 2026","format":false,"excerpt":"Is there a new trend in the journal world: \u00a0publication of interim analysis (IA) results? The NEJM recently published two articles back to back, both highlighting 9 month 'interim' data from Phase 3 pivotal trials in IgAN. The primary efficacy endpoint used in either study was UPCR at 9 months,\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":7924,"url":"https:\/\/allphasepharma.com\/dir\/2026\/10\/05\/7924\/vrg50635-lessons-learned-in-als\/","url_meta":{"origin":7499,"position":5},"title":"VRG50635 – Lessons Learned in ALS","author":"Harald","date":"October 5, 2026","format":false,"excerpt":"In a recent blog we took issue with a Nature article about \u2018Lessons learned\u2019 after a TIGIT inhibitor failed in late Phase 3 development.\u00a0 We felt that the article provided few insights, mainly platitudes. This week we saw a different kind of post-mortem.\u00a0 It was about VRG50635, a PIKfyve inhibitor\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/PLFRHIN-3-e1791227726418.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/PLFRHIN-3-e1791227726418.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/PLFRHIN-3-e1791227726418.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/PLFRHIN-3-e1791227726418.jpeg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/PLFRHIN-3-e1791227726418.jpeg?resize=1050%2C600&ssl=1 3x"},"classes":[]}],"jetpack_likes_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/07\/Avacopan-SLIDER.jpg?fit=1320%2C371&ssl=1","_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/7499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=7499"}],"version-history":[{"count":17,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/7499\/revisions"}],"predecessor-version":[{"id":7621,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/7499\/revisions\/7621"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/7498"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=7499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=7499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=7499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}